Semaglutide generics hit India
Generic versions of semaglutide have launched in India at dramatically lower prices — reports say cuts of 50–90% and copies priced as low as $14 — reshaping access to GLP‑1 therapies and consumer behavior around weight and metabolic health. That shift could accelerate demand for high‑protein and low‑sugar packaged foods, altering product‑mix forecasts and channel strategies. (livemint.com) (news.bloomberglaw.com)
Natco Pharma rolled out the first day‑one generic, pricing multi‑dose semaglutide vials at ₹1,290 per month for lower strengths and ₹1,750 for the 8 mg vial. (economictimes.indiatimes.com) Natco’s prefilled pen device pricing was published at roughly ₹4,000–4,500 per month depending on strength, with the company saying the pen format would begin wider rollout in April. (ndtvprofit.com) Sun Pharmaceutical Industries launched two branded generics — Noveltreat for chronic weight management and Sematrinity for Type‑2 diabetes — after securing DCGI/Regulatory clearance to market semaglutide in India. (sunpharma.com) Sun Pharma’s public pricing bands cite weekly therapy costs from initiation to the highest dose of about ₹900–₹2,000 for Noveltreat and about ₹750–₹1,300 for Sematrinity across available strengths. (pharma.economictimes.indiatimes.com) Dr. Reddy’s formally launched Obeda as a DCGI‑approved, once‑weekly semaglutide pen, listing the product at approximately ₹4,200 per month for the marketed strengths. (drreddys.com) Industry trackers and reports show a broad first wave of entrants — more than 40 Indian drugmakers preparing launches and media lists noting 50+ brand filings — signalling rapid fragmentation of the market. (fiercepharma.com) Brokerage and industry estimates peg the near‑term generic opportunity in India and select regulated markets at about ₹5,000 crore (₹50 billion) over 12–15 months, while sell‑side notes like Jefferies project domestic potential could approach $1 billion with strong uptake; analysts also warn export routes into markets such as Brazil and Canada will face regulatory and IP hurdles. (business-standard.com) Marketwide published price bands already span from a few hundred rupees per month on vial‑only offerings up to several thousand rupees for pen formats, reflecting deliberate product‑format segmentation by manufacturers aiming to balance unit economics and channel coverage. (theprint.in)
